A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation-Reference-Cited by-同舟云学术

A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation

Published:2019-09 Issue: Volume:178 Page:544-551
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Liang Ren-Jong,Lai Yen-Hsun,Kao Yu-Ting^ORCID,Yang Ting-Hsuan^ORCID,Chen Yen-Lun,Wang Hong-Jaan^ORCID

Funder

Ministry of Science and Technology

Hualien Armed Forces General Hospital

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference26 articles.

1. A comparision of nalbuphine with morphine for analgesic effects and safety: Meta-analysis of randomized controlled trials;Zeng;Sci. Rep.,2015

2. Opioid agonist-antagonist drugs in acute and chronic pain states;Hoskin;Drugs,1991

3. The role of science in addressing the opioid crisis;Volkow;N. Engl. J. Med.,2017

4. Nalbuphine

5. Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy;Errick;Drugs,1983

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors;Life Sciences;2024-03

2. Basic pharmacology of opioid substances;Substance Use and Addiction Research;2023

3. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse;European Journal of Medicinal Chemistry;2022-12

Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial

;Journal of Pain Research;2020-07

5. PC-FACS;Journal of Pain and Symptom Management;2020-01